Bertino Joseph S
College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Clin Ophthalmol. 2009;3:507-21. doi: 10.2147/opth.s5778. Epub 2009 Sep 24.
This article reviews the effects of the increase in bacterial resistance on the treatment of ocular infections.
Interpretive assessment.
Literature review and interpretation.
Ocular bacterial infections include conjunctivitis, keratitis, endophthalmitis, blepharitis, orbital cellulitis, and dacryocystitis. Treatment for most ocular bacterial infections is primarily empiric with broad-spectrum antibiotics, which are effective against the most common bacteria associated with these ocular infections. However, the widespread use of broad-spectrum systemic antibiotics has resulted in a global increase in resistance among both Gram-positive and Gram-negative bacteria to a number of the older antibiotics as well as some of the newer fluoroquinolones used to treat ophthalmic infections. Strategies for the prevention of the increase in ocular pathogen resistance should be developed and implemented. In addition, new antimicrobial agents with optimized pharmacokinetic and pharmacodynamic properties that have low toxicity, high efficacy, and reduced potential for the development of resistance are needed.
New antimicrobial agents that treat ocular infections effectively and have a low potential for the development of resistance could be a part of strategies to prevent the global increase in ocular pathogen resistance.
本文综述细菌耐药性增加对眼部感染治疗的影响。
解释性评估。
文献回顾与解读。
眼部细菌感染包括结膜炎、角膜炎、眼内炎、睑缘炎、眼眶蜂窝织炎和泪囊炎。大多数眼部细菌感染的治疗主要是经验性地使用广谱抗生素,这些抗生素对与这些眼部感染相关的最常见细菌有效。然而,广谱全身性抗生素的广泛使用导致全球革兰氏阳性菌和革兰氏阴性菌对许多较老的抗生素以及一些用于治疗眼部感染的新型氟喹诺酮类药物的耐药性增加。应制定并实施预防眼部病原体耐药性增加的策略。此外,需要具有优化的药代动力学和药效学特性、低毒性、高效且耐药性发展潜力降低的新型抗菌药物。
能有效治疗眼部感染且耐药性发展潜力低 的新型抗菌药物可能是预防全球眼部病原体耐药性增加策略的一部分。